Advaxis - Stock Price History | ADXS

Historical daily share price chart and data for Advaxis since 2021 adjusted for splits. The latest closing stock price for Advaxis as of October 27, 2021 is 0.49.
  • The all-time high Advaxis stock closing price was 937.03 on July 29, 2005.
  • The Advaxis 52-week high stock price is 1.57, which is 220.4% above the current share price.
  • The Advaxis 52-week low stock price is 0.26, which is 46.9% below the current share price.
  • The average Advaxis stock price for the last 52 weeks is 0.54.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Advaxis Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 0.6037 1.0900 1.3000 0.2840 0.3487 -59.34%
2019 2.4571 4.4228 7.6012 0.2485 0.8577 -69.89%
2018 22.4771 46.4768 48.5757 2.7811 2.8486 -93.31%
2017 97.2542 112.2939 143.9280 42.2789 42.5787 -60.34%
2016 134.3328 141.0795 239.5802 81.8591 107.3463 -28.83%
2015 221.1246 126.2369 431.3343 105.2474 150.8246 25.59%
2014 54.2950 61.1694 134.9325 37.6312 120.0900 88.92%
2013 97.5185 56.2219 262.3688 40.4798 63.5682 13.07%
2012 175.1124 299.8501 318.5907 56.2219 56.2219 -81.25%
2011 279.1759 224.8876 449.7751 224.8876 299.8501 33.33%
2010 294.9418 243.6282 431.0345 187.4063 224.8876 -14.29%
2009 159.5928 37.4813 318.5907 37.4813 262.3688 600.00%
2008 151.5991 318.5907 318.5907 24.3628 37.4813 -88.24%
2007 429.7652 374.8126 805.8471 262.3688 318.5907 -5.56%
2006 406.8434 393.5532 562.2189 262.3688 337.3313 -14.29%
2005 461.6384 843.3283 937.0315 299.8501 393.5532 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.072B $0.000B
Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86